$1.10
-0.08 (-6.78%)
Open$1.19
Previous Close$1.18
Day High$1.20
Day Low$1.10
52W High$2.73
52W Low$0.90
Volume—
Avg Volume64.8K
Market Cap9.64M
P/E Ratio—
EPS$-3.04
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+3,589.1% upside
Current
$1.10
$1.10
Target
$40.58
$40.58
$25.27
$40.58 avg
$56.74
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.34M | 7.69M | 6.20M |
| Net Income | 836.8K | 704.4K | 655.3K |
| Profit Margin | 11.4% | 9.2% | 10.6% |
| EBITDA | 1.33M | 1.40M | 1.15M |
| Free Cash Flow | 524.0K | 541.1K | 340.9K |
| Rev Growth | +8.2% | -3.9% | -5.2% |
| Debt/Equity | 0.19 | 0.19 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |